AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Recruiting participants (Starts Jan. 5, 2015)
Not accepting healthy volunteers
UTSW Principal Investigator: Patrick J Leavey
summary
See protocol/CiRB application
eligibility
See protocol
Participate
If you are interested in this clinical trial, please contact AMANDA RICHARDS on the Children’s Health Research Team.Call 214-456-6300Email
STU 122014-025
AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Nov 7, 2017, 7:18:10 PM UTC
Dec 12, 2024, 9:59:19 PM UTC
Patrick J Leavey
No
Yes
See protocol/CiRB application
AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed